The Pennant Group Earnings Call Transcripts
Fiscal Year 2026
-
Momentum continues following major acquisitions, with integration progressing in five waves through October. Margin expansion is targeted across segments, and a strong leadership pipeline supports both organic and acquisitional growth. Investments in technology and a flexible, local leadership model are expected to drive future value.
Fiscal Year 2025
-
Delivered strong 2025 results with 36% revenue growth and exceeded EPS guidance. 2026 outlook projects continued double-digit growth, driven by recent acquisitions, operational improvements, and robust segment performance, with a focus on integration and margin expansion.
-
Major acquisitions and organic growth drove strong 2025 results, with disciplined integration and leadership development at the core. Partnerships and JVs expanded market reach, while operational improvements in Home Health, Hospice, and Senior Living segments supported margin and occupancy gains.
-
Q3 2025 delivered record revenue, earnings, and occupancy, driven by organic growth and major acquisitions, including the UnitedHealth Amedisys deal. Full-year guidance was raised, with strong segment performance and a robust acquisition pipeline supporting future growth.
-
The group is expanding in the Southeast through acquisitions and joint ventures, emphasizing local leadership and operational efficiency. They are preparing for regulatory cuts with technology and disciplined management, and see opportunities for growth and consolidation amid industry disruption.
-
Q2 2025 saw 30% revenue growth and strong results across all segments, with raised full-year guidance and major acquisitions expanding the portfolio. Despite regulatory headwinds in home health, diversified operations and robust M&A activity support continued momentum.
-
Record Q1 2025 results with 33.7% revenue growth and 45.9% adjusted EBITDA growth, driven by strong performance in both home health/hospice and senior living segments. Integration of recent acquisitions is ahead of schedule, and guidance is trending toward the upper end of the range.
-
Strong 2024 growth was driven by strategic acquisitions, leadership development, and robust performance across home health, hospice, and senior living. The outlook for 2025 includes continued margin improvement, disciplined M&A, and investments in technology and AI to drive efficiency.
Fiscal Year 2024
-
Delivered record 2024 results with 27.6% revenue growth and 30.9% adjusted EBITDA growth, driven by strong Home Health, Hospice, and senior living performance. 2025 guidance projects continued double-digit growth, supported by strategic acquisitions, robust cash flow, and disciplined capital allocation.
-
A local leadership-driven model underpins growth across home health, hospice, and senior living, with strong post-COVID recovery and a robust M&A pipeline. Regulatory and reimbursement challenges persist, but operational flexibility, payer diversity, and investments in leadership and technology position the company for continued expansion and margin improvement.
-
Q3 2024 saw record revenue and EBITDA growth, driven by strong performance in home health, hospice, and senior living. Guidance was raised for the year, supported by a robust acquisition pipeline, zero debt, and continued operational excellence.
-
Record Q2 2024 results with 27.6% revenue growth, strong performance across all segments, and raised full-year guidance. Major acquisitions and partnerships, including Signature Healthcare at Home and Hartford HealthCare, drive a 50%+ increase in daily lives served.